Dr. Clarke Compares TKIs in EGFR+ NSCLC

Video

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, compares EGFR TKIs in EGFR-positive non–small cell lung cancer.

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, compares EGFR TKIs in EGFR-positive non—small cell lung cancer.

Both osimertinib (Tagrisso) and dacomitinib (Vizimpro) are FDA approved for the frontline treatment of this patient population, but osimertinib has emerged as the preferred agent in this setting. Clarke says that osimertinib, a third-generation EGFR TKI, has a longer median progression-free survival and a more favorable toxicity profile than dacomitinib, a second-generation irreversible pan-HER TKI.

Osimertinib appears to spare normal tissue better than other EGFR inhibitors, while dacomitinib is a potent drug, Clarke adds. Dacomitinib demonstrated an improvement in overall survival (OS) compared with gefitinib (Iressa) in the phase III ARCHER 1050 study. Researchers are still waiting for OS data with osimertinib, says Clarke. In terms of toxicity, osimertinib has lower rates of grade 3/4 adverse events with less incidence of rash and diarrhea.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute